Cordio Medical

Company Overview

Snapshot

Founded in October 2013, Cordio Medical operates with 11–50 employees and has raised $21.2 million across 7 funding rounds from 7 investors.

Business overview

Cordio Medical develops groundbreaking, medical-grade solutions for monitoring various health conditions through voice sample analysis. Its core technology, the Cordio HearO™, utilizes sophisticated proprietary algorithms and machine learning to analyze patient speech via a smartphone app, enabling near real-time monitoring and early detection of condition deterioration, particularly for congestive heart failure (CHF). The system is patient-tailored, continuously learning and providing personalized, non-invasive monitoring. Cordio Medical operates within the Health Tech & Life Sciences sector, focusing on digital healthcare, remote monitoring, and diagnostics, serving both healthcare providers and patients in markets including the United States, Israel, and Europe.

Strategic signal

In October 2023, the General Hospital of Valencia began utilizing Cordio Medical's artificial intelligence to monitor heart failure by voice, demonstrating a significant clinical validation and adoption of the company's technology. This signals a growing acceptance of AI-driven voice analysis in medical settings, indicating strong potential for Cordio Medical's expansion into major healthcare systems and further validating its non-invasive approach to chronic disease management.

Company Intelligence Q&A

What is Cordio Medical's primary technology?

Cordio Medical's primary technology is the Cordio HearO™, a voice signature AI tool that analyzes speech samples via a smartphone app to monitor health conditions, particularly congestive heart failure, by detecting fluid accumulation.

Which hospital recently adopted Cordio Medical's AI for heart failure monitoring?

In October 2023, the General Hospital of Valencia began using Cordio Medical's artificial intelligence to monitor heart failure by voice.